English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

.. Objective: Obesity is a serious disease and a precursor to other morbidities such as CVD and type 2 DM. Lifestyle modifications are recommended to control obesity along with pharmacological and surgical interventions. In this study, we evaluate the beneficial effects of orlistat in BMI reduction of obese patients in an OPD setup of Azad Jammu Kashmir. Study Design: It is a quasi-experimental placebo controlled trial. Setting: Divisional Headquarters Hospital Mirpur Azad Kashmir. Period: October 2013 to March 2014. Methods: 75 patients were enrolled having BMI of more than 27 using BMI machine model 2012. 38 Patients were randomly selected to receive orlistat 120 mg B.D for two months. 32 patients were given placebo and the reduction in BMI between the two arms was analyzed using SPSS 20. Results: After two months of study, significant reduction of 2.78 kg +/-1.718 kg in weight was observed in the study group. The reduction in average BMI in study group was 1.867 with -5.21 % reduction in BMI vs control group which had an average BMI reduction of 0.46 with -1.411% reduction in BMI. The p value is 0.001. 37.71% of patients taking orlistat reported side effects such as flatulence, fatty stools and myalgia which were 8%, 18.91% and 10.8% respectively. Conclusions: Orlistat along with life style modification is effective in BMI reduction of patients significantly as compared to placebo and may be helpful in reducing the morbidity and mortality in the long term. However, caution should be administered with orlistat because of high incidence of associated side effects.

WEIGHT REDUCTION; TO EVALUATE IN OBESE PATIENTS WITH ORLISTAT AS COMPARED TO PLACEBO USING BODY MASS INDEX IN AN OPD SETTINGS